Klifo
Klifo is recorded as a service provider in 32 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 32 trials · Latest update first
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
Sponsor USWM Ct LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure
Sponsor Pharmacosmos A/S
- Start (EU)
- Latest update
- Estimated end
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Sponsor Y-mAbs Therapeutics A/S
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma
Sponsor ADCendo ApS
- Start (EU)
- Latest update
- Estimated end
HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)
Sponsor Savara ApS
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Subjects with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Sponsor Savara ApS
- Start (EU)
- Latest update
- Estimated end
- Not reported
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
Sponsor Itb-Med AB
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa
Sponsor Xinnate AB
- Start (EU)
- Latest update
- Estimated end
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Sponsor Day One Biopharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
A Phase 1 Dose Finding and Phase 2 Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Klifo?
The 2026-10-09 snapshot links Klifo to 32 distinct CTIS trials. Recorded services include Medicinal product management, Clinical monitoring, QP release for IMPs, Regulatory services, among 20 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Klifo?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Cardiology, Gynecology, Haematological Malignancies. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Klifo conducted?
The linked trials record locations in 24 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Klifo delivered services.
What can this page tell me about Klifo's trial experience?
Browse 32 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Klifo. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- KLIFO A/S
- Klifo A/S
- Klifo GmbH